• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Amgen (AMGN)

Common Shares
Sell: $343.50|Buy: $344.40|Change: 2.80 (0.82%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introducedits first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgenalso has a growing biosimilar portfolio.

Address

One Amgen Center Drive
Thousand Oaks
CA
USA
91320-1799

Telephone

+1 805 4471060

Website

https://www.amgen.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Amgen Inc Fourth Quarter Earnings Conference Call for 20262027-02-03T13:30:00
Amgen Inc Fourth Quarter Earnings Results for 20262027-02-03T00:00:00
Amgen Inc Third Quarter Earnings Conference Call for 20262026-11-04T13:30:00
Amgen Inc Third Quarter Earnings Results for 20262026-11-04T00:00:00
Amgen Inc Second Quarter Earnings Conference Call for 20262026-08-05T13:30:00
Amgen Inc Second Quarter Earnings Results for 20262026-08-05T00:00:00
Amgen Inc Annual General Meeting for 20262026-05-22T11:00:00
Amgen Inc First Quarter Earnings Conference Call for 20262026-05-01T13:30:00
Amgen Inc First Quarter Earnings Results for 20262026-05-01T00:00:00
Amgen Inc Annual Report for 20252026-02-13T00:00:00
Amgen Inc Fourth Quarter Earnings Conference Call for 20252026-02-03T13:30:00
Amgen Inc Fourth Quarter Earnings Results for 20252026-02-03T00:00:00

Previous key dates

NameKey Date
Amgen Inc Annual Report for 20252026-02-13T00:00:00
Amgen Inc Fourth Quarter Earnings Conference Call for 20252026-02-03T13:30:00
Amgen Inc Fourth Quarter Earnings Results for 20252026-02-03T00:00:00
44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE2026-01-12T15:45:00
Citi's 2025 Global Healthcare Conference2025-12-03T13:45:00
AMGEN TO PRESENT AT THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE2025-12-03T10:00:00
Amgen Inc Third Quarter Earnings Conference Call for 20252025-11-04T13:30:00
Amgen Inc Third Quarter Earnings Result for 20252025-11-04T00:00:00
Morgan Stanley 23rd Annual Global Healthcare Conference2025-09-09T09:15:00
2025 WELLS FARGO HEALTHCARE CONFERENCE2025-09-03T10:15:00
Amgen Inc Second Quarter Earnings Conference Call for 20252025-08-05T13:30:00
Amgen Inc Second Quarter Earnings Results for 20252025-08-05T00:00:00
Amgen Conference Call from ADA 20252025-06-23T17:30:00
Jefferies Global Healthcare Conference2025-06-04T09:20:00
Amgen Inc Annual General Meeting for 20252025-05-23T11:00:00
2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE2025-05-21T09:00:00
BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE2025-05-14T09:20:00
Amgen Inc First Quarter Earnings Conference Call for 20252025-05-01T13:30:00
Amgen Inc First Quarter Earnings Result for 20252025-05-01T00:00:00
TD Cowen 45th Annual Health Care Conference2025-03-05T09:10:00
Amgen Inc Annual Report for 20242025-02-14T00:00:00
35th Annual Oppenheimer Healthcare Life Sciences Conference2025-02-12T11:20:00
Amgen Inc Fourth Quarter Earnings Conference Call for 20242025-02-04T16:30:00
Amgen Inc Fourth Quarter Earnings Result for 20242025-02-04T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.